Showing 991-1000 of 1576 results for "".
- LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Diseasehttps://modernod.com/news/lumithera-announces-first-cpt-code-to-report-photobiomodulation-therapy-in-retinal-disease/2482389/LumiThera announced a new Category III CPT code, effective January 1, 2025. The code, "Photobiomodulation therapy of retina, single session,” was approved by the AMA’s CPT Editorial Panel at the May 2024 meeting.[1] The LIGHTSITE III clinical trial was a
- Outlook Therapeutics Presents Results from NORSE EIGHT Trial Evaluating ONS-5010 for the Treatment of Wet AMDhttps://modernod.com/news/outlook-therapeutics-presents-efficacy-and-safety-results-from-norse-eight-trial-evaluating-ons-5010-for-the-treatment-of-wet-amd/2482632/Outlook Therapeutics announced the presentation of data from NORSE EIGHT at the Hawaiian Eye and Retina 2025 Meeting. Baruch D. Kuppermann, MD, PhD, of Gavin Herbert Eye Institute, University of California, Irvine, CA presented the abstract titled, “ONS-5010 (bevacizumab-vikg
- CORD Files for Premarket Approval with the FDA for the SC9 IOL for Cataract Surgeryhttps://modernod.com/news/cord-files-for-premarket-approval-with-the-fda-for-the-sc9-iol-for-cataract-surgery/2481284/Cumming Ophthalmic Research and Development (CORD) announced that it has submitted a premarket approval (PMA) application to the FDA for the Model SC9 IOL. The SC9 is the brainchild of Stuart Cumming, MD, FACS, FRCOphth, who has over one hundred patents related to IOLs. D
- American Academy of Optometry Foundation Announces Award Recipientshttps://modernod.com/news/american-academy-of-optometry-foundation-announces-award-recipients/2479474/Jonathan D. Lam, MD, OD, was this year’s recipient of the Hopkins Comprehensive Eye Care Award. Dr. Lam is a primary care/ocular disease resident at the Chinle Comprehensive Health Care Facility in Chinle, Arizona. Douglas W. Hopkins, OD, FAAO, was a leader within the Primary Care Section
- Allegro Announces Positive Results of Vehicle-Controlled Ex-US Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/allegro-announces-positive-results-of-vehicle-controlled-ex-us-phase-2-trial-of-alg-1007-for-the-treatment-of-dry-eye-disease/2479410/Allegro Ophthalmics announced that all primary and secondary endpoints of an ex-US vehicle-controlled study of ALG-1007 topical eye drop in patients with dry eye disease (DED) were met. The results were presented by Eric D. Donnenfeld, MD, at the 2021 American Society of Cataract and Refractive S
- Allegro Announces Positive Results of Ex-US Proof-of-Concept Trial With ALG-1007 for Dry Eye Diseasehttps://modernod.com/news/allegro-ophthalmics-announces-positive-results-of-ex-us-proof-of-concept-trial-with-integrin-inhibitor-alg-1007-for-dry-eye-disease/2476583/Allegro Ophthalmics announced positive results of an ex-US proof-of-concept clinical trial of the new investigational ALG-1007 topical drop drug candidate in patients with dry eye disease (DED). The results were presented by Eric D. Donnenfeld, MD, last week at the 2019 American Society of Catara
- Study Identifies "Visual System" Protein for Circadian Rhythm Stabilityhttps://modernod.com/news/study-identifies-visual-system-protein-for-circadian-rhythm-stability/2482033/Scientists at the Johns Hopkins University School of Medicine and the National Institutes of Health have identified a protein in the visual syste
- AcuFocus Announces Extended Diopter Range for the IC-8 Small Aperture IOLhttps://modernod.com/news/acufocus-announces-extended-diopter-range-for-the-ic-8-small-aperture-iol/2478087/AcuFocus announced that the IC-8 small aperture IOL power range now extends from +10.0 D to +30.0 D (0.50 D steps), offering eye care physicians the opportunity to provide more patients an uninterrupted extended range
- Centricity Vision Announces New Technologies Under Development, Zeptolink and 5.5 mm Capsulotomy; Names Leonard Borrmann to Lead R&Dhttps://modernod.com/news/centricity-vision-announces-new-technologies-under-development-zeptolink-and-55-mm-capsulotomy-names-leonard-borrmann-to-lead-rd/2480783/Centricity Vision announced two product innovations under development, the Zeptolink platform and Zepto 5.5 mm capsulotomy technology. The company has also appointed Leonard Borrmann, PharmD, to lead research and development. "The Zepto technology is elevating the precisi
- iSTAR Medical Presents Positive Results for MINIject Across Three International Glaucoma Trialshttps://modernod.com/news/istar-medical-presents-positive-results-for-miniject-across-three-international-glaucoma-trials/2480908/iSTAR Medical presented 2-year safety and efficacy results in a meta-analysis of its STAR-I, STAR-II and STAR-III clinical trials for